Saudi Arabia Intravenous Iron Drugs Market Size & Outlook
Saudi Arabia intravenous iron drugs market, 2018-2030 (US$M)
Related Markets
Saudi Arabia intravenous iron drugs market highlights
- The Saudi Arabia intravenous iron drugs market generated a revenue of USD 14.6 million in 2022 and is expected to reach USD 33.4 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 10.9% from 2023 to 2030.
- In terms of segment, ferric carboxymaltose was the largest revenue generating product in 2022.
- Other Product is the most lucrative product segment registering the fastest growth during the forecast period.
Intravenous iron drugs market data book summary
| Market revenue in 2022 | USD 14.6 million |
| Market revenue in 2030 | USD 33.4 million |
| Growth rate | 10.9% (CAGR from 2023 to 2030) |
| Largest segment | Ferric carboxymaltose |
| Fastest growing segment | Other Product |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.5% of the global intravenous iron drugs market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia intravenous iron drugs market is projected to lead the regional market in terms of revenue in 2030.
- Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 33.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 47.26% in 2022. Horizon Databook has segmented the Saudi Arabia intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose, other product covering the revenue growth of each sub-segment from 2018 to 2030.
The intravenous iron drugs market in Saudi Arabia is expected to grow at a lucrative rate over the forecast period, owing to the rapid launch of new products in the region and increasing number of government initiatives.
The completion of the study and the inclusion of medication under insurance are expected to increase patient access to treatments and, as a result, boost the demand for medicines over the forecast period. CKD burden is higher in Saudi Arabia as compared to the western world.
Based on data published in the International Journal of Nephrology published in 2019, around 6% of the total population had CKD, of which, only 7.1% were aware of their disease status. According to Globo can 2020, 27,885 cancer cases were recorded in 2020 in Saudi Arabia.
Reasons to subscribe to Saudi Arabia intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Saudi Arabia intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Saudi Arabia intravenous iron drugs market size, by product, 2018-2030 (US$M)
Saudi Arabia Intravenous Iron Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
